Viatris: Pay

Viatris paid its 5 named executives $35.9M in total in FY2025 (Dec). CEO Scott A. Smith was paid $15.3M of that.

Pay$100 in the stock at the end of FY23 → $115
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Scott A. SmithChief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
2 years
Corinne Le GoffChief Commercial Officer
FY2025 (Dec)
FY2024 (Dec)
2 years
Doretta MistrasChief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
2 years
Brian RomanFormer Chief Legal Officer
FY2025 (Dec)
FY2024 (Dec)
2 years
Andrew EnriettiChief Administrative and Transformation Officer
FY2025 (Dec)
1 year

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 7 peers with pay on file was $24.2M. The CEO of Viatris was paid $15.3M, 37% below the median.

  1. 1Gilead Sciences
  2. 2Pfizer
  3. 3Amgen
  4. 4Abbott Laboratories
  5. 5Bristol Myers Squibb
  6. 6Zoetis
  7. 7Viatris
  8. 8Regeneron Pharmaceuticals
  9. 9Bausch Health Companies Inc.Not disclosed
  10. 10Baxter InternationalNot disclosed
  11. 11BiogenNot disclosed
  12. 12Novartis AGNot disclosed
  13. 13Organon & Co.Not disclosed
  14. 14SandozNot disclosed
  15. 15Sanofi S.A.Not disclosed
  16. 16Teva Pharmaceutical LimitedNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.